MedTrace Logo

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

NCT04830137 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 248

Last updated 2026-03-20

No results posted yet for this study

Summary

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

Conditions

  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Waldenstrom Macroglobulinemia (WM)
  • Mantle Cell Lymphoma (MCL)
  • Marginal Zone Lymphoma (MZL)
  • Follicular Lymphoma (FL)
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Primary Central Nervous System Lymphoma (PCNSL)

Interventions

DRUG

NX-2127

Oral NX-2127

Sponsors & Collaborators

  • Nurix Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Study Director · Nurix Therapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-05
Primary Completion
2026-05-31
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04830137 on ClinicalTrials.gov